{"id":"minoxidil","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Angina pectoris","Cardiac tamponade","Cerebrovascular accident","Cerebrovascular disease","Chronic heart failure","Dermatosis of scalp","Disorder of cardiovascular system","Kidney disease","Myocardial infarction","Orthostatic hypotension","Pericardial effusion","Pericarditis","Pheochromocytoma"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT05888922","NCT07080931","NCT03488108","NCT01643629","NCT07076706","NCT06015516","NCT06552039","NCT05864885","NCT01309191","NCT07038941","NCT04594018","NCT05778825","NCT06826001","NCT07435012","NCT01650272","NCT03528772","NCT07502976","NCT01672307","NCT03852992","NCT06108193","NCT06043349","NCT06679556","NCT01226459","NCT01451125","NCT05636904","NCT02280603","NCT06527729","NCT04207931","NCT02206802","NCT03535233","NCT05435625","NCT07459933","NCT05827991","NCT02460497","NCT04721548","NCT07264790","NCT02486848","NCT02824380","NCT03831334","NCT00151515","NCT05839158","NCT00958750","NCT02279823","NCT03753113","NCT05296863","NCT05990400","NCT01145625","NCT04467931","NCT04481412","NCT01900041"],"aliases":["Rogaine","Regaine","Loniten (oral)"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1719/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$63","description":"MINOXIDIL 10 MG TABLET","retrievedDate":"2026-04-07"}],"allNames":"rogaine","offLabel":[],"timeline":[],"aiSummary":"Minoxidil (Rogaine) is the first FDA-approved topical treatment for hair loss, discovered serendipitously from its antihypertensive use. Available OTC as topical solution/foam. Available generically.","brandName":"Rogaine","companyId":"unknown","ecosystem":[],"mechanism":{"target":"ATP-sensitive inward rectifier potassium channel 1, Sulfonylurea receptor 2, Kir6.2","novelty":"","modality":"Small molecule","drugClass":"Vasodilator (potassium channel opener), Hair growth stimulant","explanation":"Minoxidil was originally developed as an oral antihypertensive but hair growth was noticed as a side effect. The topical formulation (Rogaine) became the first FDA-approved treatment for androgenetic alopecia. It prolongs the anagen (growth) phase of hair follicles and increases follicular size. The oral form is reserved for severe refractory hypertension.","oneSentence":"Potassium channel opener that stimulates hair follicles (topical) or causes arteriolar vasodilation (oral) for hair loss and severe hypertension.","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Generic (originally Upjohn/Pfizer)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"},{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"minoxidil","indications":{"approved":[{"name":"Alopecia","diseaseId":"alopecia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hypertensive disorder","diseaseId":"hypertensive-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05888922","phase":"Phase 3","title":"International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Pa","status":"NOT_YET_RECRUITING","sponsor":"Industrial Farmacéutica Cantabria, S.A.","isPivotal":true,"enrollment":520,"indication":"Androgenetic Alopecia, Female Pattern Baldness","completionDate":"2025-10"},{"nctId":"NCT07080931","phase":"Phase 3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia","status":"RECRUITING","sponsor":"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.","isPivotal":true,"enrollment":294,"indication":"Androgenetic Alopecia","completionDate":"2027-12"},{"nctId":"NCT03488108","phase":"Phase 1","title":"A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":20,"indication":"Alopecia","completionDate":"2019-06-17"},{"nctId":"NCT01643629","phase":"Phase 1","title":"A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic A","status":"UNKNOWN","sponsor":"Kasiak Research Pvt. Ltd.","isPivotal":false,"enrollment":20,"indication":"Androgenetic Alopecia","completionDate":"2012-11"},{"nctId":"NCT07076706","phase":"Phase 2","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","isPivotal":false,"enrollment":110,"indication":"Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)","completionDate":"2025-09-23"},{"nctId":"NCT06015516","phase":"Phase 1","title":"Randomised, Crossover Bioavailability Clinical Trial of Oral Minoxidil 1 MG, After Single and Multiple Dose Administration to Healthy Volunteers Under Fasting Conditions.","status":"COMPLETED","sponsor":"Industrial Farmacéutica Cantabria, S.A.","isPivotal":false,"enrollment":14,"indication":"Healthy","completionDate":"2024-03-08"},{"nctId":"NCT06552039","phase":"NA","title":"Scientific Evaluation of the Safety and Efficacy of Herbal and Non Herbal Formulations in Mitigating Hair Fall, Promoting Hair Growth, and Preventing Premature Hair Graying.","status":"NOT_YET_RECRUITING","sponsor":"NovoBliss Research Pvt Ltd","isPivotal":false,"enrollment":99,"indication":"Hair Fall and Pre-mature Graying","completionDate":"2024-12-24"},{"nctId":"NCT05864885","phase":"Phase 1","title":"Phase I Study of Safety and Pharmacokinetics of Once-Daily Topical Solution in Male Subjects With Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Aneira Pharma, Inc.","isPivotal":false,"enrollment":14,"indication":"Androgenetic Alopecia","completionDate":"2023-07-17"},{"nctId":"NCT01309191","phase":"NA","title":"Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","isPivotal":false,"enrollment":14,"indication":"Androgenetic Alopecia","completionDate":"2012-04"},{"nctId":"NCT07038941","phase":"Phase 1","title":"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of Single and Multiple Doses of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","isPivotal":false,"enrollment":44,"indication":"Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)","completionDate":"2024-06-02"},{"nctId":"NCT04594018","phase":"Phase 3","title":"National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopeci","status":"RECRUITING","sponsor":"EMS","isPivotal":true,"enrollment":190,"indication":"Androgenetic Alopecia","completionDate":"2027-09"},{"nctId":"NCT05778825","phase":"Phase 2","title":"A Pilot Study of Oral Minoxidil for the Treatment of Persistent Hair Loss in Pediatric, Adolescent, and Young Adult Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":10,"indication":"Survivors of Childhood Cancer, Alopecia","completionDate":"2027-03"},{"nctId":"NCT06826001","phase":"Phase 2","title":"COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","isPivotal":false,"enrollment":190,"indication":"Androgenetic Alopecia","completionDate":"2025-07"},{"nctId":"NCT07435012","phase":"Phase 3","title":"Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.","status":"RECRUITING","sponsor":"Triple Hair Inc","isPivotal":true,"enrollment":420,"indication":"Androgenic Alopecia","completionDate":"2028-04"},{"nctId":"NCT01650272","phase":"Phase 1","title":"An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA","status":"UNKNOWN","sponsor":"Siriraj Hospital","isPivotal":false,"enrollment":20,"indication":"Objective (Goal), Self-Assessment","completionDate":"2013-04"},{"nctId":"NCT03528772","phase":"NA","title":"Topical 5% Minoxidil Versus 0.2%Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure: a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Mansoura University","isPivotal":false,"enrollment":62,"indication":"Anal Fissure","completionDate":"2019-09-30"},{"nctId":"NCT07502976","phase":"NA","title":"Efficacy & Safety of Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution in Treatment of Androgenetic Alopecia: A Clinical & Biochemical Randomized Controlled Trial","status":"RECRUITING","sponsor":"Kasr El Aini Hospital","isPivotal":false,"enrollment":60,"indication":"Androgenic Alopecia","completionDate":"2027-01"},{"nctId":"NCT01672307","phase":"Phase 4","title":"Efficacy and Tolerability of Minoxidil 2% for Eyebrow Enhancement : A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study","status":"COMPLETED","sponsor":"Mae Fah Luang University Hospital","isPivotal":false,"enrollment":40,"indication":"Hypotrichosis of Eyebrows, Thinning Eyebrows","completionDate":"2013-03"},{"nctId":"NCT03852992","phase":"Phase 2","title":"The Safety and Efficacy of Fractional Ablative 10, 600nm CO2 Laser-assisted Treatments for Male Pattern Hair Loss: a Randomized Cohort Study Comparing Stand-alone Laser Treatment, Laser Assisted Drug ","status":"WITHDRAWN","sponsor":"University of Minnesota","isPivotal":false,"enrollment":0,"indication":"Male Pattern Hair Loss, Androgenetic Alopecia","completionDate":"2023-07-01"},{"nctId":"NCT06108193","phase":"Phase 1","title":"A Phase I/II Clinical Study of Topical Minoxidil in Acne Vulgaris","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","isPivotal":false,"enrollment":26,"indication":"Acne Vulgaris","completionDate":"2023-12-31"},{"nctId":"NCT06043349","phase":"Phase 4","title":"Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination Compared to Topical 5% Minoxidil Monotherapy in Male Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Indonesia University","isPivotal":false,"enrollment":36,"indication":"Androgenetic Alopecia","completionDate":"2023-09-30"},{"nctId":"NCT06679556","phase":"Phase 1","title":"A Phase 1 Randomized, Double Blind, Crossover Pharmacokinetic Study of Minoxidil Sublingual Tablets in Adult Male and Female Healthy Volunteers.","status":"COMPLETED","sponsor":"Samson Clinical Operations Pty Ltd","isPivotal":false,"enrollment":12,"indication":"Pharmacokinetic","completionDate":"2024-12-23"},{"nctId":"NCT01226459","phase":"Phase 3","title":"A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopeci","status":"COMPLETED","sponsor":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","isPivotal":true,"enrollment":404,"indication":"Androgenetic Alopecia","completionDate":"2011-08"},{"nctId":"NCT01451125","phase":"Phase 2","title":"A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of","status":"COMPLETED","sponsor":"Aderans Research Institute","isPivotal":false,"enrollment":43,"indication":"Androgenetic Alopecia, Male Pattern Baldness","completionDate":""},{"nctId":"NCT05636904","phase":"Phase 1","title":"A Proof-Of-Concept Phase 1b/2a Randomized, Vehicle, and Comparator-Controlled Study of Topical DLQ01 to Assess the Safety and Efficacy in the Treatment of Androgenetic Alopecia (AGA) in Men","status":"COMPLETED","sponsor":"Dermaliq Therapeutics, Inc.","isPivotal":false,"enrollment":120,"indication":"Androgenetic Alopecia","completionDate":"2024-03-28"},{"nctId":"NCT02280603","phase":"Phase 1","title":"A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","isPivotal":false,"enrollment":60,"indication":"Androgenetic Alopecia","completionDate":"2014-12"},{"nctId":"NCT06527729","phase":"EARLY/Phase 1","title":"Sildenafil-loaded Lipid-based Nanocarrier as a Potential Therapy for Alopecia Areata: A Randomized Clinical Study","status":"COMPLETED","sponsor":"Assiut University","isPivotal":false,"enrollment":28,"indication":"Alopecia Areata","completionDate":"2022-10-01"},{"nctId":"NCT04207931","phase":"Phase 4","title":"Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","isPivotal":false,"enrollment":250,"indication":"Central Centrifugal Cicatricial Alopecia (CCCA)","completionDate":"2027-03"},{"nctId":"NCT02206802","phase":"N/A","title":"Minoxidil Response Testing in Females With Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Applied Biology, Inc.","isPivotal":false,"enrollment":300,"indication":"Alopecia, Female Pattern Hair Loss","completionDate":"2018-10"},{"nctId":"NCT03535233","phase":"Phase 4","title":"Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Cairo University","isPivotal":false,"enrollment":40,"indication":"Alopecia Areata","completionDate":"2017-09"},{"nctId":"NCT05435625","phase":"NA","title":"Fractional Microneedling Radiofrequency Versus Fractional Carbon Dioxide Laser in Combination With Minoxidil for the Treatment of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Kasr El Aini Hospital","isPivotal":false,"enrollment":30,"indication":"Androgenic Alopecia","completionDate":"2022-12-01"},{"nctId":"NCT07459933","phase":"Phase 4","title":"Comparative Study Between Topical Methotrexate 1% Gel and Minoxidil 5% Spray in the Treatment of Localized Alopecia Areata: A Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","isPivotal":false,"enrollment":268,"indication":"Alopecia Areata","completionDate":"2026-09-15"},{"nctId":"NCT05827991","phase":"NA","title":"A Randomized Controlled Trial of the Efficacy and Safety of 1565nm Non-ablative Fractional Laser on Treating Androgenic Alopecia","status":"UNKNOWN","sponsor":"Xijing Hospital","isPivotal":false,"enrollment":75,"indication":"Androgenic Alopecia","completionDate":"2023-12-31"},{"nctId":"NCT02460497","phase":"NA","title":"Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 2% Solution and Botanical Hair Solution Regimen in Women With Thinning Hair and Female Pattern Hair Loss/And","status":"COMPLETED","sponsor":"Galderma R&D","isPivotal":false,"enrollment":61,"indication":"Female Pattern Hair Loss, Androgenic Alopecia","completionDate":"2015-09-19"},{"nctId":"NCT04721548","phase":"Phase 3","title":"A Randomized, Double Blind, Parallel-group Study to Evaluate the Efficacy and Safety of a New Pharmaceutical Form Minoxidil 5% for the Treatment of Androgenetic Alopecia in Men for 24 Weeks","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","isPivotal":true,"enrollment":336,"indication":"Alopecia","completionDate":"2024-03-06"},{"nctId":"NCT07264790","phase":"Phase 1","title":"Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Reconstruction","status":"RECRUITING","sponsor":"Duke University","isPivotal":false,"enrollment":25,"indication":"Breast Reconstruction, Perfusion; Complications","completionDate":"2027-09"},{"nctId":"NCT02486848","phase":"NA","title":"Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil","status":"WITHDRAWN","sponsor":"Maja Kovacevic, MD","isPivotal":false,"enrollment":0,"indication":"Female Pattern Hair Loss, Androgenetic Alopecia","completionDate":"2016-12"},{"nctId":"NCT02824380","phase":"Phase 1","title":"","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","isPivotal":false,"enrollment":14,"indication":"Androgenic Alopecia","completionDate":"2016-10"},{"nctId":"NCT03831334","phase":"EARLY/Phase 1","title":"An Open Label, Pilot Study Evaluating the Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","isPivotal":false,"enrollment":14,"indication":"Permanent Chemotherapy-induced Alopecia","completionDate":"2025-08"},{"nctId":"NCT00151515","phase":"Phase 3","title":"A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","isPivotal":true,"enrollment":352,"indication":"Androgenetic Alopecia","completionDate":"2004-07"},{"nctId":"NCT05839158","phase":"NA","title":"Evaluation of the Efficacy of Follicles-derived Microtissue Homogenate in Promoting Wound Healing After Hair Transplantation","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","isPivotal":false,"enrollment":100,"indication":"Wound Heal","completionDate":"2022-12-31"},{"nctId":"NCT00958750","phase":"Phase 3","title":"Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twi","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","isPivotal":true,"enrollment":113,"indication":"Androgenetic Alopecia, Female Pattern Hair Loss","completionDate":"2009-06"},{"nctId":"NCT02279823","phase":"Phase 2","title":"A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution","status":"COMPLETED","sponsor":"Intrepid Therapeutics, Inc.","isPivotal":false,"enrollment":95,"indication":"Androgenetic Alopecia","completionDate":"2016-05"},{"nctId":"NCT03753113","phase":"Phase 3","title":"Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study","status":"COMPLETED","sponsor":"Farid Masoud","isPivotal":true,"enrollment":24,"indication":"Androgenetic Alopecia","completionDate":"2019-09-02"},{"nctId":"NCT05296863","phase":"Phase 3","title":"Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial","status":"COMPLETED","sponsor":"Dr. dr. Lili Legiawati, SpKK(K)","isPivotal":true,"enrollment":37,"indication":"Alopecia, Androgenetic, Hair Loss/Baldness","completionDate":"2021-12-03"},{"nctId":"NCT05990400","phase":"Phase 2","title":"Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Indonesia University","isPivotal":true,"enrollment":40,"indication":"Androgenetic Alopecia","completionDate":"2023-12-30"},{"nctId":"NCT01145625","phase":"Phase 3","title":"A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - And","status":"COMPLETED","sponsor":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","isPivotal":true,"enrollment":322,"indication":"Alopecia","completionDate":"2012-02"},{"nctId":"NCT04467931","phase":"N/A","title":"Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans","status":"COMPLETED","sponsor":"University of Utah","isPivotal":false,"enrollment":22213,"indication":"Hypertension, COVID","completionDate":"2020-12-31"},{"nctId":"NCT04481412","phase":"Phase 2","title":"The Role of Cetirizine in Androgenetic Alopecia in Females","status":"COMPLETED","sponsor":"Cairo University","isPivotal":true,"enrollment":66,"indication":"Androgenetic Alopecia","completionDate":"2021-11-30"},{"nctId":"NCT01900041","phase":"Phase 2","title":"Multicenter, Randomised, Open Label, Comparative Clinical Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female ","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","isPivotal":false,"enrollment":74,"indication":"Female Pattern Hair Loss, Androgenetic Alopecia (AGA)","completionDate":"2013-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Topical, Oral","frequency":"Twice daily (topical)","formulation":"Topical solution, Topical foam, Tablet (oral)"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"firstApprovalDate":"1988-08-18","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":7,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}